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Edited by Peter BrzezinskiAbstract Recent studies have shown that endosomal release is a
major rate-limiting step for cellular delivery via a variety of cat-
ionic cell penetrating peptides. Thus, methods and/or protocols
for eﬀective release of endosomally entrapped drugs are highly
warranted. Photochemical internalization (PCI) has previously
been proposed for this purpose. Here, we demonstrate an
enhancement of up to two orders of magnitude of the antisense
eﬀects (cytosolic/nuclear) of peptide nucleic acid-peptide conju-
gates (Tat, Arg7, KLA) in HeLa cells by a PCI approach using
the photosensitizer AlPc2a. These results emphasize the impor-
tance of endosomal release for cellular activity of this type of
drug delivery and also raise hope that methods like PCI which
have applications for in vivo use may also enhance the bioavail-
ability and in vivo eﬃcacy of these types of conjugates.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Recently, it has been found that cellular uptake of several
cell penetrating peptide (CPP)-conjugates occurs predomi-
nantly via an endocytotic pathway [1,2] and that endosomal
escape therefore is one of the major rate-limiting steps of
CPP-mediated cellular delivery due to trapping of the CPP
conjugates in the endosomal/lysosomal compartment [1–5].
Thus the discovery and development of endosome-disruptive
methods are of great interest and several have already been de-
scribed such as Ca2+ treatment [5], chloroquine treatment [6],
sucrose treatment [7], and photochemical treatment [8].
Among these, photochemical treatment termed photochemical
internalization (PCI) may be of particular interest because it
has the potential for in vivo applications [9]. This technique
is exploiting a membrane soluble photosensitizer that produces
reactive oxygen species (ROS) upon irradiation with visible
(red) light. The ROS produced damage the endosomal mem-
brane thereby facilitating endosomal escape of the en-
trapped-compounds to the cytosol [10]. The eﬀective tissue
penetration depths of PCI is estimated to be around 2 cm
and therefore by the aid of ﬁber-optic devices, many locations*Corresponding author. Fax: +45 35396042.
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doi:10.1016/j.febslet.2006.01.077in a human body may eventually be reached by PCI treatment
[9].
It has already been demonstrated that this method can sig-
niﬁcantly improve the intracellular delivery of protein toxins
[10], plasmids [11], adenovirus vector [12] and to some extent
unmodiﬁed (anti-telomerase) peptide nucleic acid (PNA) [13].
Although the mechanism of the PCI-mediated endosomal re-
lease is not yet fully understood [9], these promising results
prompted us to test the eﬀect of PCI on the antisense potency
in cultured cells of a series of CPP conjugated PNAs which – in
contrast to ‘‘naked’’ PNAs – are known to accumulate eﬀec-
tively in endosomes [2,5].
For this purpose, we have evaluated the antisense activity of
the PNA-peptide conjugates in combination with photosensi-
tizer-mediated PCI treatment both in HeLa pLuc 705 cells
(splicing correction) and in p53R cells (translational inhibi-
tion). We demonstrate that PCI treatment can dramatically
(more than 100-fold) increase the antisense eﬀect of a number
of PNA-(cationic)peptide conjugates in HeLa cells.2. Materials and methods
2.1. Synthesis of PNAs
The sequences of the PNAs are listed in Table 1. PNA synthesis was
carried out as reported previously [14]. Cationic peptides were linked
to PNA at the N-terminal through an ethyleneglycol linker (eg1, 8-
amino-2,6-dioxaoctanoic acid) or glycine via continuous solid phase
synthesis. The PNA conjugates were puriﬁed by HPLC and character-
ized by MALDI-TOF mass spectrometry. The PNAs were lyophilized
and stored at 4 C until use.
2.2. Cell culture
HeLa pLuc705 cell and p53R cell were purchased from GENE
TOOLS (USA) and ATCC (USA), respectively. Cells were grown in
RPMI-1640 medium (Sigma) supplemented with 10% fetal bovine serum
(FBS), 1% glutamax (Gibco), penicillin (100 U/ml) and streptomycin
(100 lg/ml) at 37 C in humidiﬁed air with 5% CO2. For the studies
of HeLa pLuc705 cells in 96 well plate format, cells were trypsinized
and seeded (1.2 · 104 cells/well) 16 h before treatment. For the studies
in 24-well plate, 7.2 · 104 cells/well were used.
2.3. PNA treatment and PCI
The photosensitizer AlPcS2a (Aluminum phthalocyanine, Frontier
Scientiﬁc, Logan, USA) of 5 lg/ml was added to the medium for the
PCI treatments. The cells, replated in 96-well or 24-well plates 16 h ear-
lier in the presence of AlPcS2a (5 lg/ml), were treated with 100 ll/well
(for 96-well plate) or 0.3 ml/well (for 24-well plate) of OPTI-MEM
(Gibco) containing the PNA at the designated concentration for 4 h.
Then the OPTI-MEM was replaced with the same volume of fresh
growth medium (RPMI-1640 containing 10% FBS and 1% glutamax)
and incubated further for 4 h and the cells were subsequently exposedblished by Elsevier B.V. All rights reserved.
Table 1
Sequences and nomenclature of the PNAs used in this study
PNA sequence target PNA no. Sequencea
Splicing correction (HeLa pLuc 705 cell) 2389 H-CCT CTT ACC TCA GTT ACA-NH2
2737 H-(D-Arg)6-Gly-CCT CTT ACC TCA GTT ACA-NH2
2785 H-(D-Arg)7-Gly-CCT CTT ACC TCA GTT ACA-NH2
2787 H-(D-Arg)8-Gly-CCT CTT ACC TCA GTT ACA-NH2
2738 H-(D-Arg)9-Gly-CCT CTT ACC TCA GTT ACA-NH2
2392 H-(L-Arg)7-eg1-CCT CTT ACC TCA GTT ACA-NH2
2395 H-Tat-eg1-CCT CTT ACC TCA GTT ACA-NH2
2393 H-NLS-eg1-CCT CTT ACC TCA GTT ACA-NH2
2394 H-KFF-eg1-CCT CTT ACC TCA GTT ACA-NH2
2744 H-KLA-Gly-CCT CTT ACC TCA GTT ACA-NH2
2822 H-(D-Arg D-Lys)3-Gly-CCT CTT ACC TCA GTT ACA-NH2
2824 H-(D-Arg D-Lys)4-Gly-CCT CTT ACC TCA GTT ACA-NH2
2826 H-(D-Arg D-Arg D-Ala)3-Gly-CCT CTT ACC TCA GTT ACA-NH2
2828 H-(D-Arg D-Arg D-Ala)4-Gly-CCT CTT ACC TCA GTT ACA-NH2
2830 H-(D-Arg)4(D-Lys)4-Gly-CCT CTT ACC TCA GTT ACA-NH2
2831 H-(D-Arg)4(D-Lys)4-Gly- CCT CTT ACC TCA GTT ACA-NH2
2832 H-(D-Lys)2(D-Arg)4(D-Lys)2-Gly-CCT CTT ACC TCA GTT ACA-NH2
2747 H-Tat-eg1-CCT CTG ACC TCA TTT ACA-NH2
Antisense luciferase (p53R cells) 2880 H-(D-Arg)7-Gly-GCG TCT TCC ATG GTG-NH2
eg1, 8-amino-3,6-dioxaoctanoyl (‘‘ethyleneglycol linker’’); Tat, GRKKRRQRRRPPQ; NLS, PKKKRKV; KFF, KFFKFFKFFK; KLA,
KLALKLALKALKAALKLA.
PNA2747 is mismatch control (Tat-PNA-MM) for the PNA2395 (Tat-PNA) where the mismatches are indicated in bold.
aThe sequences of peptides and PNAs are written from N-terminal to C-terminal-end. The sequences of CPP are written using either standard three
letter symbols or abbreviations.
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FO18, 7.77 lW/cm2 at 650–680 nm with the highest intensity around
660 nm) and incubated further for 24 h before analysis.
2.4. Luciferase assay
At 24 h after irradiation, the cells were subjected to luciferase activ-
ity analysis by using the Bright-Glo Luciferase assay system (Promega)
or the Luciferase Assay System (Promega) for the cells in 96-well plates
or the cells in 24-well plates, respectively. Measurements were per-
formed according to the manufacturer’s instructions. Luminescent
readings obtained with Bright-Glo-Luciferase assay system were back-
ground-subtracted and are presented as relative light units (RLU). For
the luciferase assay with Luciferase Assay System, cells were lysed with
Passive Lysis Buﬀer (Promega) and used for the assay. Luminescent
readings obtained with Luciferase Assay System were background-
subtracted and normalized by protein concentrations and are pre-
sented as RLU/mg protein. For the luminescent readings from p53R
cell study, the value of RLU/mg protein from non-PNA treated sample
was set as 100%. Protein concentrations were determined by BCA pro-
tein assay (Pierce) according to the manufacturer’s instruction.
2.5. Cytotoxicity test
At 24 h after light irradiation, the cells in the 96-well plate were sub-
jected to an MTS-assay for cell viability by using the CellTiter 96
Aqueous Non-Radioactive Cell Proliferation Assay (Promega) accord-
ing to the manufacturer’s instructions. The absorbance is presented as
relative cellular viability (absorbance from non-PNA treated cells was
set as 100%).
2.6. RT-PCR
Total RNA was extracted from the cellular lysate prepared for the
luciferase assay by using RNeasy Mini kit (Qiagen) and subjected to
RT-PCR analysis. RT-PCR was performed by using OneStep RT-
PCR kit (Qiagen). A total of 3 ng RNA was used for each RT-PCR
reaction (20 ll). Primers for the RT-PCR were as follows: forward pri-
mer, 5 0-TTGATATGTGGATTTCGAGTCGTC-3 0; reverse primer,
5 0-TGTCAAT-CAGAGTGCTTTTGGCG-3 0. The RT-PCR program
was as follows: {(55 C, 35 min) · 1 cycle, (95 C, 15 min) · 1 cycle,
(94 C, 0.5 min; 55 C, 0.5 min; 72 C, 0.5 min) · 29 cycles}. RT-
PCR products were analyzed on 2% agarose gel with 1· TBE buﬀer
and visualized by ethidium bromide staining. Gel image were captured
by ImageMaster (Pharmacia Biotech) and analyzed by UN-SCAN-IT
software (Silk Scientiﬁc corporation).3. Results and discussion
The PNA-peptide conjugates listed in Table 1 (splicing
correction) were studied. The peptides include the well
known biologically derived Tat peptide [2] and nuclear local-
ization signal peptide (NLS) [15], and the artiﬁcial oligo
arginine [16] and KLA peptides [17] all of which have been
reported to facilitate PNA delivery in eukaryotic cells, as
well as the bacterial delivery peptide ‘‘KFF’’ [18], and a ser-
ies of novel Arg/Lys peptides. These peptides were all via
continuous solid phase synthesis conjugated to a PNA oligo-
mer targeting the cryptic splice site within the luciferase gene
in HeLa pLuc705 cells. The nuclear antisense eﬀect (as a po-
sitive luciferase activity readout) in this cellular system pro-
vides a quantitative measure that makes it possible to
compare the relative nuclear uptake of the diﬀerent PNA
conjugates [5,19].
In a primary screening of the PNA conjugates, HeLa
pLuc705 cells were treated with the conjugates and the eﬀect
of PCI treatment was assessed by comparing the antisense
activity in combination with or without irradiation
(Fig. 1). In the absence of light, naked PNA showed very
little antisense activity in this very sensitive assay system,
whereas increased activity was seen for PNA conjugated to
oligoarginine ((L-Arg)7, (D-Arg)8, (D-Arg)9 and the model
amphipathic peptide, KLA (Fig. 1B). It should be noted,
however, that the luciferase activation observed only corre-
sponds to a few percent of splicing correction (vide infra,
Figs. 3 and 4). It is also noteworthy that the PNA-KLA
conjugate is quite active, in good agreement with previous
uptake results [17]. However, at higher concentrations
(>3 lM) this conjugate showed severe cellular toxicity (data
not shown, vide infra, Fig. 2). Furthermore, the (L-Arg)7
conjugate (PNA2392) showed higher activity than the corre-
sponding D-Arg conjugate (PNA2785) despite the fact that
the D-peptide should be biologically more stable. In general,
PNA (1 µM)
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Fig. 1. Eﬀect of the PCI treatment on the nuclear antisense eﬀects of the PNAs conjugated to a variety of CPP. HeLa pLuc 705 cells, preincubated
with photosensitizer AlPcS2a (5 lg/ml), were transfected with PNA (1 lM) for 4 h and replaced with the growth medium for further incubation. After
4 h incubation, cells were subjected to the red light irradiation (10 min) and incubated further for 24 h. Then the cells were subjected to luciferase
activity analysis. Luciferase activity is presented as RLU. Each bar represents the mean ± S.D. of three independent experiments. (A) The numbers
on top of the bars indicate fold increase of the light irradiated sample (light) relative to the non-light irradiated sample (dark). (B) RLUs of cells
transfected with the PNA (0.3, 1 or 3 lM) without irradiation (dark). It is important to note that RLU is a relative and not an absolute measure that
cannot be directly compared between independent experiments, and much less between diﬀerent studies.
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sense activity in combination with PCI treatment and the
photosensitizer itself did not show any eﬀect on the PNA
activity without visible light irradiation (vide infra). In par-
ticular, we note that the activity of the naked PNA
(PNA2389) was enhanced less than 3-fold, whereas that of
(L-Arg)7-PNA (PNA2392) and Tat-PNA (PNA2395) in-
creased 75- and 116-fold, respectively. Interestingly, the
PNA conjugated to KLA peptide (PNA2744) and Tat pep-
tide showed equal (and highest) activity in combination with
PCI treatment, although the activity of the KLA conjugate
was only enhanced 12-fold. The NLS and the KFF retained
low activity even with PCI treatment. These results clearly
indicate the potential of the PCI treatment for enhancing
the cellular delivery of some antisense PNA-peptide conju-
gates, and also (not surprisingly) demonstrate that the mech-
anism(s) for cellular uptake diﬀers between the peptides as
they exhibit great variation in terms of PCI activation.
For instance, endosomal entrapment seems more pro-nounced for the Tat conjugate as compared to the KLA
and the oligoarginine conjugates, which are relatively much
more active without PCI treatment and do therefore either
more eﬃciently escape the endosomes by themselves and/or
to some extent enter cells by a non-endocytotic pathway.
More elaborate dose–response experiments (Fig. 2A) con-
ﬁrmed and expanded the results obtained from the screening
data in Fig. 1. In combination with PCI treatment, Tat-PNA
induced slightly higher luciferase activity than (L-Arg)7-PNA
and KLA-PNA. Furthermore, Tat-PNA and especially
KLA-PNA showed relatively higher cytotoxicity compared
to (L-Arg)7-PNA (Fig. 2B). Indeed, the antisense eﬀect of the
KLA-PNA (in contrast to Tat-PNA and (L-Arg)7-PNA) did
not increase from 2 to 4 lMmost likely due to cellular toxicity.
As a further characterization of the PCI enhanced antisense ef-
fect, we performed a series of control experiments demonstrat-
ing that treatment of the cells with the sensitizer alone did not
have any signiﬁcant eﬀect on neither the luciferase activity nor
on the luciferase mRNA splicing correction (Fig. 3). Only the
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Fig. 2. Eﬀect of PCI treatment on the nuclear antisense activity of the
PNAs conjugated to heptaarginine ((L-Arg)7-PNA, PNA2392), Tat
peptide (Tat-PNA, PNA2395) and KLA peptide (KLA-PNA,
PNA2744). HeLa pLuc 705 cells were treated as described in the
legend for Fig. 1 with 0–4 lM PNA. Each data represents the
mean ± S.D. of three independent experiments. (A) Luciferase activity
of light irradiated samples (light) and non-irradiated samples (dark).
(B) Cellular viability of the cells treated with PNA in combination with
PCI treatment (AlPcS2a and light irradiation). Cellular viability was
determined by MTS assay (Promega) and absorbance from non-PNA
treated sample was set as 100%.
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Fig. 3. Eﬀects of AlPcS2a treatment and/or light irradiation on the
luciferase activity and splicing correction by Tat-PNA. HeLa pLuc705
cells were cultured in 24-well plates in the absence or presence of
AlPcS2a (5 lg/ml) and treated with Tat-PNA (PNA 2395, 1 lM) as
described in the legend to Fig. 1. (A) Luciferase activity assay. The
measured and background-subtracted luciferase activity was normal-
ized by protein concentration and is presented as RLU/mg protein.
Each data point represents the mean ± S.D. of three independent
experiments. (B) RT-PCR analysis of the mis-splicing correction of
pre-mRNAs. Total RNA was extracted form the same lysate sample
used in Fig. 3A and subjected to RT-PCR. Uncorrected (268 bp)
indicates the fragments without splicing correction, and corrected
(142 bp) indicates the splicing corrected fragments. Numbers under
each lane indicate the amount of the corrected form relative to the sum
of corrected and uncorrected form.
1454 T. Shiraishi, P.E. Nielsen / FEBS Letters 580 (2006) 1451–1456combination of sensitizer, light and PNA was eﬀective. Finally,
we addressed the sequence speciﬁcity of the PCI enhanced anti-
sense eﬀect by using a sequence mismatched control (Tat-
PNA-MM, PNA2747) (Fig. 4). These data clearly show that
only the matched and not the mis-matched PNA-Tat conju-
gate induced PCI enhanced luciferase activity (Fig. 4A). Fur-
thermore, the luciferase activity data are fully correlated with
the eﬀect of splicing correction as measured by RT-PCR anal-
ysis (Fig. 4B). Finally, we compared the eﬀect of co-treatment
with PCI with that of the lysomotrophic agent chloroquine,
which has been shown to enhance the antisense eﬀect of
PNA-Tat conjugates via endosome/lysozome release [5]. The
results analyzed by luciferase activity as well as by RT-PCR
splicing correction determination (Fig. 5) show that the activa-
tion by PCR is comparable to (>50%) that obtained by an
optimal concentration of chloroquine, and it should be possi-
ble to further optimize the PCI co-treatment procedure in
terms of concentration, time and time lapse parameters.
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Fig. 4. Eﬀects of PCI treatment on the antisense activity of Tat-PNA
and a mismatch PNA control. HeLa pLuc705 cells were cultured in 24-
well plates in the presence of AlPcS2a(5 lg/ml) and treated with PNA
(Tat-PNA (PNA2395) and its mismatch PNA (Tat-PNA MM, PNA
2747) at the indicated concentrations as described in the legend to
Fig. 1. (A) The measured and background-subtracted luciferase
activity was normalized by protein concentration and is presented as
RLU/mg protein. Each data point represents the mean ± S.D. of three
independent experiments. (B) RT-PCR analysis as described in Fig. 3.
Numbers under each lane indicate the amount of the corrected form
relative to the sum of corrected and uncorrected form.
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Fig. 5. Comparison of PCI treatment and chloroquine (CQ) treatment
on the antisense activity of Tat-PNA. Tat-PNA and PCI treatment of
the HeLa pLuc705 cells were performed as indicated in the legend for
Fig. 1. For the CQ treatment, 120 lM CQ was added to the PNA
solution before addition to the cells. After 24 h incubation, cells were
subjected to the further analysis. (A) Luciferase activity assay. The
measured and background-subtracted luciferase activity was normal-
ized by protein concentration and is presented as RLU/mg protein.
Each data point represents the mean of two independent experiments.
(B) RT-PCR analysis. Relative amounts of the corrected form were
determined as indicated in Fig. 3. Because of the comparison to the
PCI treatment, the present CQ activation results are not quantitatively
comparable to our previous results [5]. In the present experiments the
cells were exposed to the PNA for only 4 h.
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cellular system only reﬂects the amount of the PNA in the
nucleus because the target is pre-mRNA. The size of the
CPP-PNA conjugates (<10 kDa) is small enough to allow
simple diﬀusion between nucleus and cytosol through the
nuclear pore complex, and consequently comparable concen-
trations of the PNA in the cytosol and in the nucleus would
be anticipated. In order to assay for active PNA in the cyto-
sol, we performed antisense experiments on p53R cells which
express normal luciferase mRNA using a PNA targeting
translation initiation (which is a cytosolic event). We focused
on the heptaarginine conjugated PNA (PNA2880, Table 1)
because of its low cytotoxicity and synthetic simplicity. As
shown in Fig. 6, a signiﬁcant enhancement of the antisense
eﬀect is seen upon PCI treatment (light) as compared to
control (dark). Indeed, without PCI augmentation the
PNA-conjugate showed no downregulation of luciferase
expression while a dose-dependent decrease of luciferase
activity (IC50 = 6.3 lM) was seen upon PCI co-treatment.
Unfortunately, it is not possible from these data to compare
quantitatively the concentrations of PNA in the cytosol ver-
sus the nucleus as the antisense inhibition events are diﬀer-
ent and are diﬀerently sensitive to PNA inhibition.
However, the results very clearly show that also the cyto-solic eﬀect and thus the active concentration of the PNA
is very signiﬁcantly enhanced by PCI treatment.
In conclusion our data show that PCI co-treatment can very
signiﬁcantly enhance the antisense eﬀect and thus by inference
the cellular delivery of (some) PNA-peptide conjugates (pre-
sumably be releasing endosomally trapped PNA conjugate),
although the relative eﬀect diﬀers for diﬀerent peptides. This
is particularly encouraging in view of the fact that essentially
analogous photodynamic therapy is being employed in ongo-
ing clinical anticancer trials, and therefore there is an exciting
potential that PCI enhancement of the activity of anticancer
drugs based on further optimized and developed PNA conju-
gates could in the future be employed for in vivo applications
and eventually also in the clinic.
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Fig. 6. Eﬀect of the PCI treatment for the cytosolic antisense eﬀects of
the heptaarginine-PNA conjugate (PNA2880) targeting luciferase
mRNA translation. The p53R cells were treated as described in the
legend for Fig. 1 with 0–10 lM PNA. Luciferase activity was
normalized by protein concentrations and is shown as relative
luciferase activity (non-PNA treated samples was set as 100%). Each
data point represents the mean of three independent experiments. The
dose–response inhibitory eﬀects of PNA were sigmoidal and could be
ﬁtted to a Hill slope (IC50 of 6.3 lM and n.d. for the PCI treated and
non-treated samples, respectively).
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